問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Orthopedics

更新時間：2023-09-19

莊啟政Chuang, Chi-Cheng
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • ccc2915@cgmh.org.tw

Recruiting Trial

7Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

莊啟政

List

10Cases

2026-01-01 - 2030-12-31

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2018-02-02 - 2021-01-17

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-03-01 - 2026-12-31

Phase II

Active
A Phase II, Randomized, Open-Label, Parallel-Group Autologous Dendritic Cell Vaccination as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

  • Condition/Disease

    Glioblastoma Multiforme (GBM)

  • Test Drug

    ADCV01

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2025-01-01 - 2031-06-30

Phase III

Active
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of Vorasidenib (S095032/AG-881) in Asian Participants with Residual or Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation

  • Condition/Disease

    Residual or Recurrent Grade 2 IDH Mutant Glioma

  • Test Drug

    Vorasidenib

Participate Sites
2Sites

Recruiting2Sites

2020-06-01 - 2027-12-31

Phase I/II

Active
Phase 1B Trial of ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme

  • Condition/Disease

    Newly Diagnosed Glioblastoma Multiforme (GBM)

  • Test Drug

    ADI-PEG 20

Participate Sites
6Sites

Recruiting6Sites

2015-05-01 - 2020-06-11

Phase II

ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group

  • Condition/Disease

    Glioblastoma Multiforme (GBM)

  • Test Drug

    ABT-414

Participate Sites
5Sites

Terminated5Sites

魏國珍
Linkou Chang Gung Medical Foundation

Division of Orthopedics

2015-10-15 - 2020-04-22

Phase III

A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma Multiforme (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification. (Intellance1)

  • Condition/Disease

    Glioblastoma Multiforme (GBM)

  • Test Drug

    ABT-414

Participate Sites
3Sites

Terminated3Sites

魏國珍
Linkou Chang Gung Medical Foundation

Division of Orthopedics

2023-12-01 - 2026-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2016-07-01 - 2019-12-31

Phase I/II

A Phase I/ II Study of CAN008 Plus Concomitant Temozolomide During and After Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme

  • Condition/Disease

    Glioblastoma Multiforme (GBM)

  • Test Drug

    CAN008(APG101)

Participate Sites
3Sites

Terminated3Sites

魏國珍
Linkou Chang Gung Medical Foundation

Division of General Surgery

2025-01-01 - 2031-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB